Tumour stem cell-targeted treatment: elimination or = differentiation -- Massard et al. 17 (11): 1620 -- Annals of = Oncology

Annals of=20 Oncology Advance Access originally published online on May 3, 2006=20
Annals of = Oncology 2006=20 17(11):1620-1624; doi:10.1093/annonc/mdl074

This = Article

	Full=20 Text
	= Full=20 Text (PDF)
	All Versions of this=20 Article: 17/11/1620 most recent mdl0= 74v3=20 mdl0= 74v2=20
	E= -letters:=20 Submit a response
	Alert=20 me when this article is cited
	Ale= rt=20 me when E-letters are posted
	Alert=20 me if a correction is posted

Services

	Email=20 this article to a friend
	Similar=20 articles in this journal
	Similar=20 articles in ISI Web of Science
	Similar=20 articles in PubMed
	Alert me to=20 new issues of the journal
	Add=20 to My Personal Archive
	Download=20 to citation manager
	Search for citing = articles in:=20 ISI=20 Web of Science (3)
	Request=20 Permissions
	Disclai= mer=20

Google = Scholar

	Articles by Massard, C =
	Articles by Soria, J-C =
	Search for Related Content =

PubMed

	PubMed=20 Citation
	Articles by Massard, C =
	Articles by Soria, J-C=20

=A9=20 2006 European Society for Medical Oncology

reviews

Tumour stem cell-targeted treatment: elimination or differentiation=20

C Massard¹, E=20 Deutsch² and J-C = Soria¹^,*=20

¹ Department of Medicine, Institut Gustave = Roussy,=20 Villejuif, France
² Department of Radiation Oncology, = Institut=20 Gustave Roussy, Villejuif, France

^* Correspondence to: Dr J.-C. = Soria,=20 Department of Medicine, Institut Gustave Roussy, 39 rue C. Desmoulins,=20 Villejuif, France. Tel: +33-142114301; Fax: +33-142115230; E-mail: soria{at}igr.fr

A wide range of studies suggest that most cancers are = clonal⁼²⁰and may represent the progeny of a single cell, a cancer stem⁼cell (CSC) endowed with the capacity to maintain tumour = growth.⁼²⁰The concept of a cancer stem cell emerged decades ago, and = the⁼²⁰haematopoietic system is where it has mostly gained ground.⁼²⁰More recently, CSC have been described in breast cancer and⁼²⁰brain tumours. Growing evidence suggests that pathways = regulating⁼²⁰normal stem cell self-renewal and differentiation are also = present⁼²⁰in cancer cells and CSC. Malignant tumours can be viewed as⁼an=20 abnormal organ in which a small population of tumourigenic⁼cancer=20 stem cells have escaped the normal limits of self-renewal⁼giving rise=20 to abnormally differentiated cancer cells that contributeto = tumour=20 progression and growth. This new model has important⁼implications for=20 the study and treatment of cancer. Understandingthe = molecular=20 circuitry which contributes to the maintenanceof stem cells = may=20 provide an insight into the molecular mechanismsof cancer = and thus=20 new approaches for elimination or differentiationtherapy. = Therapies=20 targeting CSC should focus on pathways suchas Wnt, Shh and = Notch=20 which are required for the maintenanceof cancer stem cells, = but also=20 on the ABC transporter familyand other specific properties = of cancer=20 stem cells.

Key words: cancer stem cell, differentiation, leukaemia, = self-renewal, solid=20 tumours, targeted therapy

This article has been cited by other=20 articles:=20

3D"Home
3D"Ann
M. Mimeault and S. K. Batra
Interplay of = distinct=20 growth factors during epithelial mesenchymal transition of cancer=20 progenitor cells and molecular targeting as novel cancer=20 therapies
Ann. Onc., October 1, 2007; = 18(10): 1605 -=20 1619.
[Abstract]=20 [Fu= ll=20 Text] [PDF]=20
=20

				M. Mimeault and S. K. Batra Interplay of = distinct=20 growth factors during epithelial mesenchymal transition of cancer=20 progenitor cells and molecular targeting as novel cancer=20 therapies Ann. Onc., October 1, 2007; = 18(10): 1605 -=20 1619. [Abstract]=20 [Fu= ll=20 Text] [PDF]=20 =20